Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy

Published:2016-10-26 Issue:4 Volume:119 Page:579-584
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Sonpavde Guru¹,Pond Gregory R.²,Mullane Stephanie³,Ramirez Ana A.⁴,Vogelzang Nicholas J.⁴,Necchi Andrea⁵,Powles Thomas⁶,Bellmunt Joaquim³

Affiliation:

1. UAB Comprehensive Cancer Center; Birmingham AL USA

2. McMaster University; Hamilton ON Canada

3. Dana-Farber Cancer Institute and Harvard Medical School; Boston MA USA

4. Comprehensive Cancer Centers of Nevada; Las Vegas NV USA

5. Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

6. Barts Cancer Institute; London UK

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13674/fullpdf

Reference17 articles.

1. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma;McCaffrey;J Clin Oncol,1997

2. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group;Roth;J Clin Oncol,1994

3. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

5. Plimack ER Gupta S Bellmunt J et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer ESMO Congress 2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era;Clinical Genitourinary Cancer;2023-12

2. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy;Clinical Genitourinary Cancer;2022-12

3. Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study;Biomedicines;2022-09-09

4. Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy;Future Oncology;2021-11

5. Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis;Urologic Oncology: Seminars and Original Investigations;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3